Drug intelligence / Profile preview

Hyal-Plus (Elliott Labs)

Development stage
Unknown
Lead developer
Elliott Labs
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Hyal-Plus is an oral nutraceutical combination product developed and marketed by Elliott Labs for the management of joint disorders, including osteoarthritis, rheumatoid arthritis, facet arthropathy, and ankylosing spondylitis. Formulated as a tablet, it contains a synergistic blend of Rosehip extract, Boswellia serrata extract, Vitamin C (ascorbic acid), and piperine. Boswellia serrata extract acts as an allosteric inhibitor of arachidonate 5-lipoxygenase (ALOX5), reducing the synthesis of inflammatory leukotrienes. Rosehip extract contains anti-inflammatory galactolipids (such as GOPO) that inhibit leukocyte chemotaxis and cytokine secretion, thereby protecting cartilage from degradation. Vitamin C serves as an essential cofactor for prolyl 4-hydroxylase, promoting collagen synthesis and cartilage repair. Piperine acts as a bioenhancer by inhibiting drug-metabolizing enzymes (such as CYP3A4) and efflux transporters (such as P-glycoprotein/ABCB1), which increases the absorption and bioavailability of the other active ingredients while also providing mild anti-inflammatory benefits.

Brand names
HYAL PLUSHyal-Plus
Other names
Rosehip / Boswellia / Vitamin C / PiperineRosehip extract + Boswellia serrata + ascorbic acid + piperine
02

Targets

ALOX5 (Arachidonate 5-lipoxygenase)CYP3A4 (Cytochrome P450 3A4)ABCB1 (P-glycoprotein)P4H (Prolyl 4-hydroxylase subunit alpha-3)

Beyond the preview

Go deeper on Hyal-Plus (Elliott Labs).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hyal-Plus (Elliott Labs).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call